UPTAKE AND DIFFUSION OF PHARMACEUTICAL INNOVATIONS IN HEALTH SYSTEMS - Innovation in the Biopharmaceutical Industry - page 102

Ellison, S et al . (1997). Characteristics of demand for pharmaceutical products an exami-
nation of four cephalosporins. Rand Journal of Economics , 28(3), 426-446.
Fattore, G and C Jommi (1998). The new pharmaceutical policy in Italy. Health Policy ,
46(1), 21-41.
Ferlie, E, L Fitzgerald and M Wood (2000). Getting evidence into clinical practice: an
organisational behaviour perspective. Journal of Health Services Research and Policy ,
5(2), 96-102.
Fitzgerald, L, E Ferlie and C Hawkins (2003). Innovation in healthcare: how does credible
evidence influence professionals? Health & Social Care in the Community , 11(3),
219-228.
Fortess, EE et al . (2001). Utilization of essential medications by vulnerable older people
after a drug benefit cap: importance of mental disorders, chronic pain, and practice
setting. Journal of American Geriatric Society , 49(6), 793-797.
Freemantle, N (1999). Does the UK National Health Service need a fourth hurdle for
pharmaceutical reimbursement to encourage the more efficient prescribing of pharma-
ceuticals? Health Policy , 46(3), 255-265.
Ganslandt, M and KE Maskus (2004). Parallel imports and the pricing of pharmaceutical
products: evidence from the European Union. Journal of Health Economics , 23(5),
1035-1057.
Gerdtham, UG (1996). The impact of user charges on the consumption of drugs: empirical
evidence and economic implications. Pharmacoeconomics , 9(6), 478-483.
Gianfrancesco, FD, AP Baines and D Richards (1994). Utilization effects of prescription
drug benefits in an aging population. Health Care Financing Review , 15(3).
Giuliani, G, G Selke and L Garattini (1998). The German experience in reference pricing.
Health Policy , 44(1), 73-85.
Goodwin, FK (2003). Impact of formularies on clinical innovation. Journal of Clinical
Psychiatry , 64(Suppl 17), 11-14.
Grabowski, H (1988). Medicaid patients' access to new drugs. Health Affairs , 7(5),
102-114.
Greenhalgh, T, G Robert, P Bate, F Macfarlane and O Kyriakidou (2005). Diffusion of
Innovations in Health Service Organisations: A Systematic Literature Review . Oxford:
Blackwell.
Griffiths, RI et al . (1994). A review of the first year of medicare coverage of erythropoietin.
Health Care Financing Review , 15(3), 83-102.
Grootendorst, PV et al . (2001). Impact of reference-based pricing of nitrates on the use and
costs of anti-anginal drugs. Canadian Medical Association Journal , 165(8), 1011-
1019.
Grootendorst, PV et al . (2005). The impact of reference pricing of nonsteroidal anti-
inflammatory agents on the use and costs of analgesic drugs. Health Services Research ,
40(5 Pt 1), 1297-1317.
Harris, BL, A Stergachis and LD Ried (1990). The effect of drug co-payments on utiliza-
tion and cost of pharmaceuticals in a health maintenance organization. Medical Care ,
28(10), 907-917.